The Moderna mRNA-1273 vaccine works by delivering a synthetic strand of messenger RNA, wrapped in a microscopic fat bubble, into your cells. Once inside, the mRNA instructs your cellular machinery to produce a stabilized version of the SARS-CoV-2 spike protein, which your immune system then recognizes and builds defenses against. In its large Phase 3 trial, the vaccine showed about 94% efficacy against symptomatic COVID-19 and nearly complete protection against severe disease.1PubMed. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine The technology behind it, though, had been in development for years before the pandemic forced it into the spotlight.
The Lipid Nanoparticle That Delivers the Message
Naked mRNA injected into your body would be destroyed within minutes by enzymes in your tissues. The solution is a delivery vehicle called a lipid nanoparticle, or LNP, essentially a tiny sphere made of specially designed fat molecules that shields the mRNA and ferries it into cells. The Moderna vaccine uses an ionizable lipid called SM-102 as its key ingredient. This lipid is electrically neutral at normal body pH, which keeps the particle stable in the bloodstream, but it picks up a positive charge once it enters the slightly acidic interior of a cell’s endosome, the compartment that engulfs incoming particles.
That charge shift is what triggers escape. As SM-102 becomes positively charged inside the endosome, it pairs with negatively charged lipids in the endosomal membrane, destabilizing it and releasing the mRNA into the cell’s main interior, where the protein-building machinery lives. Research comparing different ionizable lipids found that SM-102 mediated more efficient protein production than alternatives, partly because its chemical properties make it better at accepting protons at the relevant pH range.2PubMed Central. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability The LNP also contains cholesterol for structural stability, a helper lipid that aids membrane fusion, and a polyethylene glycol (PEG)-coated lipid that prevents the particles from clumping together.
Engineering a Spike That Holds Its Shape
The mRNA inside the vaccine does not encode just any version of the SARS-CoV-2 spike protein. It encodes a deliberately modified version locked into what researchers call the “prefusion” conformation, the shape the spike holds before it fuses with a human cell. This matters because the prefusion shape exposes the parts of the protein that your immune system most needs to see in order to produce effective neutralizing antibodies. If the spike were allowed to collapse into its post-fusion shape, those critical surfaces would be hidden.
To keep the spike locked in prefusion form, researchers introduced two proline amino acid substitutions at positions where the protein normally undergoes a dramatic structural rearrangement. Proline is rigid and acts like a molecular brace. Subsequent structure-guided work screened over 100 spike variants and identified that additional proline substitutions could boost protein stability even further, with the best variant showing roughly ten-fold higher expression and withstanding heat stress, room-temperature storage, and repeated freeze-thaw cycles while maintaining its prefusion shape.3PubMed Central. Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes The two-proline version (called 2P) was the design used in the authorized Moderna and Pfizer vaccines, while the six-proline variant (called HexaPro) informed next-generation vaccine design.
Modified Nucleosides and Cleaner Manufacturing
Even inside a lipid shell, synthetic mRNA faces another problem: your cells are wired to detect foreign RNA and sound an alarm. Pattern-recognition receptors inside cells can distinguish natural mRNA from lab-made mRNA, triggering an inflammatory response that both reduces how much protein gets produced and can cause excessive side effects. The workaround is a chemical substitution. In the Moderna vaccine, every uridine nucleoside in the mRNA strand is replaced with a modified version called N1-methylpseudouridine. This swap makes the mRNA essentially invisible to the cell’s innate immune sensors while also improving the efficiency of protein translation.
The nucleoside modification alone is not enough, though. The manufacturing process that produces mRNA through in vitro transcription also generates impurities, most importantly double-stranded RNA (dsRNA), a potent trigger of inflammation. Research has confirmed that both the nucleoside modification and the reduction of dsRNA impurities are necessary to fully control the immune-activating profile of therapeutic mRNA.4PubMed Central. Impact of mRNA chemistry and manufacturing process on innate immune activation Moderna and other manufacturers have invested in purification strategies and engineered enzymes to minimize these byproducts during production.5PubMed Central. Process and analytical strategies for the safe production of mRNA vaccines and therapeutics
What Happens After the Shot
Once injected into your upper arm, the lipid nanoparticles are taken up by cells near the injection site, including muscle cells and immune cells like dendritic cells. Inside these cells, the mRNA is read by ribosomes, which translate its instructions into copies of the stabilized spike protein. Some of those spike proteins are displayed on the surface of the cell, and some are broken down into fragments and presented on the cell surface via molecules that act as signaling flags for the immune system.6PubMed Central. Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines
This presentation kicks off two branches of the adaptive immune response. B cells recognize the spike protein and begin producing antibodies, including neutralizing antibodies that can block the virus from entering cells. Meanwhile, T cells are activated: CD4+ “helper” T cells support the antibody response and coordinate the broader immune effort, and CD8+ “killer” T cells learn to destroy any cell displaying spike-protein fragments, which would include cells actually infected by the virus. The LNP component itself also contributes, acting as a built-in adjuvant that amplifies the immune response independently of the mRNA cargo.7PubMed Central. Innate immune mechanisms of mRNA vaccines
The mRNA itself is degraded by the cell within days. No part of the vaccine enters the cell nucleus or interacts with your DNA.
From Sequence to First Human Dose in 66 Days
When the genetic sequence of SARS-CoV-2 was published on January 11, 2020, Moderna’s team selected the spike protein as the vaccine target and designed the mRNA construct within days. By February 24, the first clinical batch had been shipped to the National Institutes of Health for use in a Phase 1 trial, a gap of just 66 days from sequence to first-in-human dosing. The Phase 1 study tested three dose levels: 25, 100, and 250 micrograms. Antibody responses rose with increasing dose after both the first and second injections, and after the second dose, neutralizing antibody levels in all participants were comparable to or exceeded those found in people who had recovered from COVID-19.8New England Journal of Medicine. An mRNA Vaccine against SARS-CoV-2 – Preliminary Report
A follow-up study in older adults confirmed that the 100-microgram dose produced stronger antibody responses than the 25-microgram dose, which supported moving forward with 100 micrograms for the large efficacy trial.9PubMed Central. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults This speed was possible not because safety steps were skipped but because the mRNA platform allowed the vaccine construct to be designed computationally and manufactured synthetically, without needing to grow live virus or use cell cultures. Regulatory agencies also ran review steps in parallel rather than sequentially.
Phase 3 Efficacy
The COVE trial enrolled about 30,000 participants across the United States. In the initial analysis, symptomatic COVID-19 was confirmed in 185 people who received the placebo and just 11 who received the vaccine, yielding an efficacy of about 94%. All 30 cases of severe COVID-19, including one death, occurred in the placebo group.1PubMed. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine By the time the blinded phase of the trial was completed and more follow-up data were available, efficacy against symptomatic illness held at about 93%, and efficacy against severe disease was about 98%.10PubMed. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
Immune Memory Beyond Antibodies
Antibody levels inevitably decline in the months after vaccination. That decline led to widespread concern about “waning immunity,” but antibodies are only one layer of protection. Research tracking vaccinated individuals over six months found that while antibody levels dropped from their peak, memory B cells, the cells that can rapidly churn out new antibodies upon re-exposure, actually increased from three to six months after vaccination. Most of these memory B cells could cross-recognize multiple variants, including Alpha, Beta, and Delta. Early CD4+ T cell responses correlated with longer-lasting antibody production, suggesting that a strong initial T cell response helps sustain humoral immunity.11PubMed Central. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
A separate study examining the 25-microgram dose found that spike-specific memory CD4+ T cells six months after the second dose were comparable in quantity and quality to those seen in people who had recovered from COVID-19, and spike-specific CD8+ T cells were generated in 88% of subjects with equivalent memory at six months.12PubMed Central. Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells In practical terms, this means that even as your antibody titers fall, your immune system retains a trained reserve that can be mobilized quickly if you encounter the virus. This durable cellular memory is a major reason why vaccinated individuals continued to enjoy strong protection against hospitalization and death even months after their last dose, when circulating antibody levels had dropped substantially.
The Role of Frailty and Age
Older and frailer adults tend to mount weaker immune responses to vaccines in general, and the Moderna vaccine is no exception to this pattern. A study examining frail older adults found that higher frailty was associated with lower antibody levels after the initial two-dose series. However, after a booster dose, all participants showed improved antibody levels and the differences attributable to frailty or prior infection were no longer statistically significant. The same study found that both CD4+ and CD8+ T cell responses were positively linked to the overall antibody response.13PubMed Central. Frailty and Age Impact Immune Responses to Moderna COVID-19 mRNA Vaccine This was a reassuring finding: even in the population where vaccine responses are weakest, a booster dose largely closed the gap.
Myocarditis and Other Safety Signals
The most discussed serious adverse event linked to mRNA vaccines is myocarditis, inflammation of the heart muscle. Cases have been reported after both the Moderna and Pfizer vaccines, predominantly in younger males within a few days of the second dose. A case report described a healthy 22-year-old male who developed pleuritic chest pain three days after his first dose of the Moderna vaccine; imaging confirmed perimyocarditis with wall motion abnormalities.14BMC Cardiovascular Disorders. Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report
Population-level surveillance has consistently shown that vaccine-associated myocarditis is rare, on the order of a few cases per hundred thousand doses in the highest-risk group (young men aged roughly 16 to 30). The vast majority of cases are mild, resolve on their own or with standard anti-inflammatory treatment, and involve short hospital stays. Importantly, the risk of myocarditis from a COVID-19 infection itself is higher than the risk from vaccination, a comparison that weighed heavily in regulatory decisions to continue recommending the vaccine for all eligible age groups. Some countries responded to the signal by preferentially recommending the Pfizer vaccine for younger males, since the Moderna vaccine’s higher mRNA dose (100 micrograms versus 30 micrograms) was associated with a somewhat higher rate of myocarditis in that demographic.
Cold Chain and Storage Challenges
One of the practical hurdles of mRNA vaccines is their fragility. mRNA is inherently unstable and degrades quickly at room temperature. The original Moderna formulation required storage at minus 20 degrees Celsius for long-term use, though it could be kept in a standard refrigerator for up to 30 days before use. This was considerably more forgiving than the Pfizer vaccine’s initial minus 70-degree requirement, but still posed significant challenges for distribution in low-resource settings. Many countries lacked the cold-chain infrastructure to execute mass vaccination campaigns with either product.15PubMed Central. Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines Subsequent formulation improvements extended refrigerator stability, and the prefusion-stabilized spike designs discussed earlier contributed to overall product robustness.
Government Investment and Patent Disputes
The Moderna vaccine was not a purely private-sector achievement. The U.S. government, through the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense, co-developed the vaccine throughout its lifecycle and invested more than $18 billion, including guaranteed advance purchases of hundreds of millions of doses and direct funding for clinical trials and manufacturing capacity. This public investment substantially de-risked the development process.16PubMed Central. US public investment in development of mRNA covid-19 vaccines: retrospective cohort study
The vaccine’s success also sparked fierce intellectual property battles. Competing claims over the fundamental technologies involved, including the lipid nanoparticle delivery system, the modified mRNA designs, and the method of stabilizing the spike protein, led to complex patent disputes among multiple biotechnology companies and research institutions.17PubMed Central. The patent dispute over the breakthrough mRNA technology The pioneering work on nucleoside-modified mRNA by Katalin Karikó and Drew Weissman, conducted years before the pandemic, was central to several of these disputes and ultimately recognized with the 2023 Nobel Prize in Physiology or Medicine.
Adapting to Variants
One of the core promises of the mRNA platform is speed of adaptation. When a new variant emerges, you can swap the genetic sequence in the mRNA construct without changing anything about the manufacturing process or the lipid nanoparticle. Moderna demonstrated this by developing bivalent boosters that combined mRNA encoding the original Wuhan-Hu-1 spike with mRNA encoding the Omicron BA.1 spike, each at 25 micrograms for a total 50-microgram dose.18PubMed Central. A Bivalent Omicron-Containing Booster Vaccine against Covid-19 Later formulations targeted BA.4/BA.5 and subsequent subvariants, following the same approach. This modular design has allowed mRNA vaccines to be updated on a timeline closer to that of seasonal flu vaccines, something that would have been impossible with traditional vaccine manufacturing platforms that depend on growing virus in eggs or cell cultures.
How Moderna Compares to Pfizer-BioNTech
The two authorized mRNA COVID-19 vaccines share the same core technology but differ in several details. The Moderna vaccine delivers 100 micrograms of mRNA per dose (reduced to 50 micrograms for boosters), while the Pfizer-BioNTech vaccine delivers 30 micrograms. Both use N1-methylpseudouridine-modified mRNA and encode the prefusion-stabilized spike, but they use different ionizable lipids in their nanoparticles: SM-102 for Moderna and ALC-0315 for Pfizer.2PubMed Central. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability Initial efficacy estimates were similar, with the Moderna vaccine at about 94% and the Pfizer vaccine at about 95% against the original strain.19European Review for Medical and Pharmacological Sciences. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines
Real-world data over time suggested that Moderna’s higher dose may have conferred slightly longer-lasting protection, with several observational studies finding that effectiveness against infection declined more slowly for the Moderna vaccine than for the Pfizer vaccine in the months following the second dose. The flip side of the higher dose is a somewhat higher rate of reactogenicity, meaning sore arms, fatigue, and fever were reported more often, and as noted earlier, a modestly higher rate of myocarditis in young men. Moderna’s storage advantage, minus 20 versus minus 70 degrees, made it more practical for rural clinics and mobile vaccination units, though both products eventually achieved similar refrigerator-stable shelf lives with updated formulations.
Vaccination During Pregnancy and Transplacental Transfer
A concern raised early in the vaccination campaign was whether the mRNA or spike protein produced by the vaccine could cross the placenta and reach the fetus. Research examining maternal blood, placental tissue, and cord blood at delivery found no detectable vaccine mRNA or spike protein in any of those samples. What did transfer was protective: anti-SARS-CoV-2 IgG antibodies were detected in about 95% of maternal blood samples and about 88% of cord blood samples at delivery. All mother-infant pairs with positive antibodies at delivery showed transfer of functional neutralizing antibodies. By follow-up, about 82% of infants still had detectable IgG, with one infant remaining positive at 12 weeks of age.20PubMed Central. Evaluation of transplacental transfer of mRNA vaccine products and functional antibodies during pregnancy and infancy In other words, the vaccine’s products stayed in the mother, but the protective antibodies it generated crossed the placenta and persisted in newborns during their earliest and most immunologically vulnerable weeks.